Editorial: Safety consideration in the development of anti-tumor monoclonal antibodies during drug development
Saved in:
| Main Authors: | Tao Wang, Shaad Essa Abedin, Jan Willem van der Laan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1640377/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The physiological limits of bispecific monoclonal antibody tissue targeting specificity
by: Armin Sepp, et al.
Published: (2025-12-01) -
Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches
by: Sherif A. El-Kafrawy, et al.
Published: (2025-06-01) -
Antibody drug conjugates
by: Stalin Bala, et al.
Published: (2020-01-01) -
Physiologically Based Pharmacokinetic Modeling of Biologic Case Studies in Monkeys and Humans Reveals the Necessity of an Additional Clearance Term
by: Felix Stader, et al.
Published: (2025-04-01) -
Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01)